Palatin Technologies Says Vyleesi Licensee Fosun Pharma Reports First Commercial Sale In China
Portfolio Pulse from Benzinga Newsdesk
Palatin Technologies announced that its Vyleesi licensee, Fosun Pharma, has reported its first commercial sale in China. Additionally, Palatin's South Korean licensee, Kwangdong Pharmaceuticals, has completed enrollment in its Phase 3 clinical trial for Vyleesi. The data from this trial is expected by the end of the year, with a potential regulatory submission in the first half of 2024.
August 08, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palatin Technologies' Vyleesi has made its first commercial sale in China through Fosun Pharma. Additionally, Kwangdong Pharmaceuticals has completed Phase 3 trial enrollment for Vyleesi.
The first commercial sale of Vyleesi in China is a significant milestone for Palatin Technologies, indicating market acceptance and potential revenue growth. The completion of Phase 3 trial enrollment by Kwangdong Pharmaceuticals also suggests progress in the drug's development and potential expansion of its market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100